Clinical Trial Update: Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating safety of a recombinant adeno-associated virus delivering acid alpha-glucosidase for Pompe disease has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (AAV-AAG Latent enzyme delivery vector for Pompe disease)

Snippet

Sponsor: University of Florida | Conditions: Pompe Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-11-17